GlassScriptPhysician profile
Tara Draehn
NPI 1194315739
$35,025.35
in general payments reported to CMS, 2019-2025
39 companies · $4,565 in 2025
The $4,565 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,161 · 2022: $4,928 · 2023: $17K · 2024: $5,716 · 2025: $4,565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Food and Beverage: $4,126 · Travel and Lodging: $786 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,523.75 |
| Food and Beverage | $4,126.08 |
| Travel and Lodging | $786.45 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $23,151.70 | 2021-2025 | |
| Spinal Simplicity, LLC | $3,863.78 | 2021-2024 | Ha Minuteman G3-R |
| Surgentec | $2,288.41 | 2022-2023 | Tilink, Ion Facet Screw System |
| Relievant Medsystems, INC. | $1,089.62 | 2022-2023 | Intracept |
| Pacira Pharmaceuticals Incorporated | $764.61 | 2023-2024 | Iovera, Exparel, Zilretta |
| Grt US Holding, INC. | $508.61 | 2021-2022 | |
| Dexcom, INC. | $351.56 | 2024-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $335.77 | 2022-2025 | Repatha, Otezla, Evenity |
| Boston Scientific Corporation | $319.59 | 2021 | |
| Si-Bone, INC. | $296.66 | 2021 | |
| Azurity Pharmaceuticals, INC. | $261.16 | 2023-2024 | Horizant, Horizant |
| Averitas Pharma INC. | $240.66 | 2023-2024 | Qutenza |
| Astrazeneca Pharmaceuticals LP | $184.28 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Arbor Pharmaceuticals, INC. | $155.51 | 2021-2022 | |
| Almatica Pharma LLC | $113.92 | 2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Draehn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.